keyword
MENU ▼
Read by QxMD icon Read
search

fenofibrate and diabetes

keyword
https://www.readbyqxmd.com/read/29790265/lipid-lowering-medication-use-is-associated-with-decreased-risk-of-diabetic-retinopathy-and-its-treatments-in-patients-with-type-2-diabetes-a-real-world-observational-analysis-of-a-health-claims-database
#1
Ryo Kawasaki, Tsuneo Konta, Kohji Nishida
AIMS: Fenofibrate and statins reduced the risk of diabetic retinopathy (DR) related treatment in clinical trials. We aimed to determine whether lipid-lowering medication use reduce the risk of DR and its treatments in patients with type 2 diabetes using a real-world health claims database. METHODS: This was an observational analysis using a nation-wide health claims database of the Japan Medical Data Center (JMDC). Type 2 diabetes was defined by the ICD-10 codes with glucose-lowering medication use...
May 22, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29789213/severe-hypertriglyceridemia-clinical-characteristics-and-therapeutic-management
#2
Walter Masson, Emiliano Rossi, Daniel Siniawski, Juan Damonte, Ana Halsband, Ramiro Barolo, Miguel Scaramal
INTRODUCTION: The therapeutic management of severe hypertriglyceridaemia represents a clinical challenge. OBJECTIVES: The objectives of this study were 1) to identify the clinical characteristics of patients with severe hypertriglyceridaemia, and 2) to analyse the treatment established by the physicians in each case. METHODS: A cross-sectional study was carried out using the computerised medical records of all patients>18 years of age with a blood triglyceride level≥1,000mg/dL between 1 January 2011 and 31 December 2016...
May 19, 2018: Clínica e Investigación en Arteriosclerosis
https://www.readbyqxmd.com/read/29763709/fenofibrate-effects-on-carotid-artery-intima-media-thickness-in-adults-with-type-2-diabetes-mellitus-a-field-substudy
#3
Jason A Harmer, Anthony C Keech, Anne-Sophie Veillard, Michael R Skilton, Gerald F Watts, David S Celermajer
AIM: Dyslipidemia in type 2 diabetes contributes to an increased risk of cardiovascular disease. Fenofibrate, a lipid-regulating peroxisome proliferator-activated receptor-α (PPARα) agonist, has been shown to reduce vascular complications in adults with type 2 diabetes. The mechanisms for such benefit, however, are not yet well understood. We examined the effects of fenofibrate on carotid intima-media thickness (IMT), a marker of subclinical atherosclerosis, in adults with type 2 diabetes...
May 12, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29761900/fenofibrate-improves-renal-function-by-amelioration-of-nox-4-il-18-and-p53-expression-in-an-experimental-model-of-diabetic-nephropathy
#4
Habib Yaribeygi, Mohammad T Mohammadi, Ramin Rezaee, Amirhossein Sahebkar
Among several pathological mechanisms involved in diabetic nephropathy, oxidative stress, inflammation, and apoptosis play a prominent role. Fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, has markedly improved oxidative stress and inflammatory responses, but there is no evidence about its effects on interleukin-18 (IL-18), NADPH oxidase type 4 (NOX-4), and p53 expression in diabetic kidneys. The aim of this study was to evaluate possible effects of fenofibrate on improving the underlying mechanisms of diabetic nephropathy...
May 15, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29745912/clinical-case-report-on-acute-pancreatitis-with-concomitant-t2dm-and-hypertriglyceridemia
#5
T Magradze, E Shelestova
Authors present a clinical case review of a 46-years-old, otherwise healthy female patient, presented with acute abdominal pain. Examination and full work-up established a diagnosis of acute pancreatitis, T2DM and hypertriglyceridemia; based on family history, inherited hypertriglyceridemia was suspected. Elevated TG values associated with diabetes dramatically increase the risk of developing MI. Subsequent to the pancreatitis treatment protocol completion, the patient has fully recovered from acute pancreatitis...
April 2018: Georgian Medical News
https://www.readbyqxmd.com/read/29671030/abnormal-islet-sphingolipid-metabolism-in-type-1-diabetes
#6
Laurits J Holm, Lars Krogvold, Jane P Hasselby, Simranjeet Kaur, Laura A Claessens, Mark A Russell, Clayton E Mathews, Kristian F Hanssen, Noel G Morgan, Bobby P C Koeleman, Bart O Roep, Ivan C Gerling, Flemming Pociot, Knut Dahl-Jørgensen, Karsten Buschard
AIMS/HYPOTHESIS: Sphingolipids play important roles in beta cell physiology, by regulating proinsulin folding and insulin secretion and in controlling apoptosis, as studied in animal models and cell cultures. Here we investigate whether sphingolipid metabolism may contribute to the pathogenesis of human type 1 diabetes and whether increasing the levels of the sphingolipid sulfatide would prevent models of diabetes in NOD mice. METHODS: We examined the amount and distribution of sulfatide in human pancreatic islets by immunohistochemistry, immunofluorescence and electron microscopy...
April 18, 2018: Diabetologia
https://www.readbyqxmd.com/read/29669526/the-effect-of-fenofibrate-on-early-retinal-nerve-fiber-layer-loss-in-type-2-diabetic-patients-a-case-control-study
#7
Rui Shi, Lei Zhao, Yun Qi
BACKGROUND: Previous studies suggested that use of fenofibrate could significantly reduce the rate of progression into diabetic retinopathy (DR), and that retinal nerve fiber layer (RNFL) loss, which has been considered an important indicator for retinal neurodegeneration, might precede microvascular changes. The aim of this study was to assess the effect(s) of fenofibrate on RNFL thickness at early stage of DR in patients with type 2 diabetes mellitus (DM). METHODS: In this retrospective matched case-control study we included a cohort of 89 patients with type 2 DM, aged 40 or above, between Jan 1, 2017 and March 31, 2017...
April 18, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29496472/effect-of-fenofibrate-on-uric-acid-and-gout-in-type-2-diabetes-a-post-hoc-analysis-of-the-randomised-controlled-field-study
#8
Boris Waldman, Jean-Claude Ansquer, David R Sullivan, Alicia J Jenkins, Neil McGill, Luke Buizen, Timothy M E Davis, James D Best, Liping Li, Michael D Feher, Christelle Foucher, Y Antero Kesaniemi, Jeffrey Flack, Michael C d'Emden, Russell S Scott, John Hedley, Val Gebski, Anthony C Keech
BACKGROUND: Gout is a painful disorder and is common in type 2 diabetes. Fenofibrate lowers uric acid and reduces gout attacks in small, short-term studies. Whether fenofibrate produces sustained reductions in uric acid and gout attacks is unknown. METHODS: In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, participants aged 50-75 years with type 2 diabetes were randomly assigned to receive either co-micronised fenofibrate 200 mg once per day or matching placebo for a median of 5 years follow-up...
April 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29493554/elevated-triglycerides-and-low-high-density-lipoprotein-cholesterol-level-as-marker-of-very-high-risk-in-type-2-diabetes
#9
Michel P Hermans, Paul Valensi
PURPOSE OF REVIEW: The aim of this review is to describe in diabetic patients the determinants underlying atherogenic dyslipidemia, a complex dyslipidemia defined as the coexistence of fasting hypertriglyceridemia and low high-density lipoprotein cholesterol level. Atherogenic dyslipidemia is often comorbid with hyperglycemia in patients with the common form of type 2 diabetes mellitus (T2DM), namely that associated with obesity, insulin resistance, hyperinsulinemia and the metabolic syndrome phenotype...
April 2018: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/29472432/predicting-the-effect-of-fenofibrate-on-cardiovascular-risk-for-individual-patients-with-type-2-diabetes-mellitus
#10
Charlotte Koopal, Frank L J Visseren, Jan Westerink, Yolanda van der Graaf, Henry N Ginsberg, Anthony C Keech
OBJECTIVE: In clinical trials, treatment with fenofibrate did not reduce the incidence of major cardiovascular events (MCVE) in patients with type 2 diabetes mellitus (T2DM). However, treatment effects reported by trials comprise patients who respond poorly and patients who respond well to fenofibrate. Our aim was to use statistical modeling to estimate the expected treatment effect of fenofibrate for individual patients with T2DM. RESEARCH DESIGN AND METHODS: To estimate individual risk, the FIELD risk model, with 5-year MCVE as primary outcome, was externally validated in T2DM patients from ACCORD and the SMART observational cohort...
February 22, 2018: Diabetes Care
https://www.readbyqxmd.com/read/29436756/alirocumab-vs-usual-lipid-lowering-care-as-add-on-to-statin-therapy-in-individuals-with-type-2-diabetes-and-mixed-dyslipidaemia-the-odyssey-dm-dyslipidemia-randomized-trial
#11
Kausik K Ray, Lawrence A Leiter, Dirk Müller-Wieland, Bertrand Cariou, Helen M Colhoun, Robert R Henry, Francisco J Tinahones, Maja Bujas-Bobanovic, Catherine Domenger, Alexia Letierce, Rita Samuel, Stefano Del Prato
AIM: To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY DM-DYSLIPIDEMIA trial (NCT02642159). MATERIALS AND METHODS: The UC options (no additional lipid-lowering therapy; fenofibrate; ezetimibe; omega-3 fatty acid; nicotinic acid) were selected prior to stratified randomization to open-label alirocumab 75 mg every 2 weeks (with increase to 150 mg every 2 weeks at week 12 if week 8 non-HDL cholesterol concentration was ≥2...
June 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29433142/ppar-%C3%AE-agonist-improves-hyperglycemia-induced-oxidative-stress-in-pancreatic-cells-by-potentiating-antioxidant-defense-system
#12
Habib Yaribeygi, Mohammad Taghi Mohammadi, Amirhossein Sahebkar
BACKGROUND: Diabetes-induced oxidative stress has an essential role in pancreatic cells dysfunction. The present study aimed to evaluate whether peroxisome proliferator activated receptor- alpha (PPAR-α) induction by fenofibrate counterbalances oxidative stress in pancreatic cells. METHODS: In this in vivo study, male Wistar rats were randomly divided into four groups as normal, normal treated, diabetic and diabetic treated groups (n=6 in each group). Diabetes was induced by a single intravenous injection of streptozotocin (45 mg/kg)...
February 12, 2018: Drug Research
https://www.readbyqxmd.com/read/29313565/utilisation-of-lipid-lowering-therapies-in-outpatient-settings-in-poland-epidemiological-survey-economedica-dyslipidaemia-2015
#13
Filip M Szymański, Anna E Płatek, Anna Ryś, Karolina Semczuk-Kaczmarek, Bartosz Krzowski, Katarzyna Wróbel, Krzysztof J Filipiak
BACKGROUND: Dyslipidaemia, especially elevated low-density lipoprotein cholesterol (LDL-C), is one of the most important cardiovascular risk factors. Treatment of dyslipidaemia and prevention of cardiovascular disease (CVD) with lipid-lowering drugs is one of the key issues in reducing cardiovascular mortality. Nevertheless, underutilisation of statins and lipid-lowering drugs is still a problem globally. AIM: The present study aimed to describe the utilisation of lipid-lowering drugs in groups of patients with indications for statin treatment and elevated LDL-C...
2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29283132/efficiency-of-fenofibrate-in-facilitating-the-reduction-of-central-macular-thickness-in-diabetic-macular-edema
#14
Srilakshmi Srinivasan, Prathibha Hande, Jyoti Shetty, Sindhu Murali
PURPOSE: The purpose of this study is to study the benefit of addition of oral fenofibrate to the current regimen of diabetic macular edema (DME) management and quantify its effect on macular thickness and visual function in DME. METHODS: Fifty-three eyes of 50 patients were randomized into treatment (Group A) (oral fenofibrate 160 mg/day) and control groups (Group B). Both groups underwent treatment of DME as per the standard treatment protocol of our hospital including intravitreal injections (anti-vascular endothelial growth factor/steroid) and grid laser...
January 2018: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29238904/anti-inflammatory-activity-of-anti-hyperlipidemic-drug-fenofibrate-and-its-phase-i-metabolite-fenofibric-acid-in-silico-in-vitro-and-in-vivo-studies
#15
G Shyam Prasad, P Govardhan, G Deepika, V Vakdevi, R B Sashidhar
Fenofibrate, an anti-hyperlipidemic drug and its phase-I biotransformed metabolite fenofibric acid, was studied for COX-1 (PDB ID: 3N8Y) and COX-2 (PDB ID: 1PXX) inhibition potentials in silico and in vitro for their effects on human recombinant COX-2 enzyme isolated from a Baculovirus expression system in sf21 cells (EC 1.14.99.1) using a conventional spectrophotometric assay. Furthermore, the compounds were also screened for their anti-inflammatory potentials in vivo using carrageenan-induced paw oedema method in Wistar rats...
December 13, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/29236863/evaluation-of-phenolic-compounds-and-lipid-lowering-effect-of-morus-nigra-leaves-extract
#16
Ana Lúcia B Zeni, Tatianne D Moreira, Ana Paula Dalmagro, Anderson Camargo, Larissa A Bini, Edésio L Simionatto, Dilamara R Scharf
Morus nigra L. (Moraceae) is a tree known as black mulberry and the leaves are used in folk medicine in the treatment of diabetes, high cholesterol and menopause symptoms. The aim of this study was to evaluate the M. nigra leaves phytochemical profile in different extractions and the hypolipidemic effect of the infusion comparing to the fenofibrate. Morus nigra infusion (MN) showed higher amounts of phenolics and flavonoids (83.85 mg/g and 79.96 µg/g, respectively), as well as antioxidant activity (83.85%) than decoction or hydromethanolic extracts...
December 7, 2017: Anais da Academia Brasileira de Ciências
https://www.readbyqxmd.com/read/29182629/effects-of-peroxisome-proliferator-activated-receptors-ppar-%C3%AE-and-%C3%AE-agonists-on-cochlear-protection-from-oxidative-stress
#17
Marijana Sekulic-Jablanovic, Vesna Petkovic, Matthew B Wright, Krystsina Kucharava, Nathan Huerzeler, Soledad Levano, Yves Brand, Katharina Leitmeyer, Andrea Glutz, Alexander Bausch, Daniel Bodmer
Various insults cause ototoxicity in mammals by increasing oxidative stress leading to apoptosis of auditory hair cells (HCs). The thiazolidinediones (TZDs; e.g., pioglitazone) and fibrate (e.g., fenofibrate) drugs are used for the treatment of diabetes and dyslipidemia. These agents target the peroxisome proliferator-activated receptors, PPARγ and PPARα, which are transcription factors that influence glucose and lipid metabolism, inflammation, and organ protection. In this study, we explored the effects of pioglitazone and other PPAR agonists to prevent gentamicin-induced oxidative stress and apoptosis in mouse organ of Corti (OC) explants...
2017: PloS One
https://www.readbyqxmd.com/read/29163755/uncoupling-protein-2-a-key-player-and-a-potential-therapeutic-target-in-vascular-diseases
#18
REVIEW
Giorgia Pierelli, Rosita Stanzione, Maurizio Forte, Serena Migliarino, Marika Perelli, Massimo Volpe, Speranza Rubattu
Uncoupling protein 2 (UCP2) is an inner mitochondrial membrane protein that belongs to the uncoupling protein family and plays an important role in lowering mitochondrial membrane potential and dissipating metabolic energy with prevention of oxidative stress accumulation. In the present article, we will review the evidence that UCP2, as a consequence of its roles within the mitochondria, represents a critical player in the predisposition to vascular disease development in both animal models and in humans, particularly in relation to obesity, diabetes, and hypertension...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29099085/eburicoic-acid-a-triterpenoid-compound-from-antrodia-camphorata-displays-antidiabetic-and-antihyperlipidemic-effects-in-palmitate-treated-c2c12-myotubes-and-in-high-fat-diet-fed-mice
#19
Cheng-Hsiu Lin, Yueh-Hsiung Kuo, Chun-Ching Shih
This study was designed to investigate the antidiabetic and antihyperlipidemic effects and mechanisms of eburicoic acid (TRR); one component of Antrodia camphorata in vitro and in an animal model for 14 weeks. Expression levels of membrane glucose transporter type 4 (GLUT4); phospho-5'-adenosine monophosphate-activated protein kinase (AMPK)/total AMPK; and phospho-Akt/total-Akt in insulin-resistant C2C12 myotube cells were significantly decreased by palmitate; and such decrease was prevented and restored by TRR at different concentrations...
November 2, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29062184/a-case-of-massive-hypertriglyceridemia-in-6-year-old-boy
#20
Purvi Purohit, Daisy Khera, Praveen Sharma, Kuldeep Singh
Type V hypertriglyceridemia in children is a rare condition since it has often been associated with obesity, type II diabetes, metabolic syndrome and hormone therapy. We encountered a case of massive hypertriglyceridemia (1900 mg/dl) in a 6 years old boy with complains of acute pancreatitis but no physical manifestations. There was no family history of sudden cardiac death, father and younger male sibling were found to be normal. The mother however had hypertriglyceridemia. The child was managed by dietary changes, omega 3 capsules and low dose fenofibrate...
October 2017: Indian Journal of Clinical Biochemistry: IJCB
keyword
keyword
76738
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"